TrialsgrambetaRCTs are beautiful

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

This guideline cites 16 of the 199 landmark trials in our Cardiology register.

The US guideline restructures atrial fibrillation as a disease continuum in four stages (at risk, pre-AF, AF, permanent AF) rather than by episode duration, and it anchors the decision to anticoagulate on an estimated annual thromboembolic risk of ≥2% rather than on a fixed score cut-off, allowing scores other than CHA₂DS₂-VASc. The ESC 2024 guideline arrives at a similar place from another direction, dropping sex from the score entirely (CHA₂DS₂-VA). The sharper difference is the left atrial appendage occluder, which the ACC/AHA upgraded to Class 2a for patients with a non-reversible contraindication to long-term anticoagulation, while the ESC keeps it at IIb. Note the timing: the guideline's evidence review closed before NOAH-AFNET 6 and ARTESiA reported on device-detected AF — both appear in the final section below.

Stroke prevention: anticoagulation5

  • 2013ENGAGE AF-TIMI 48⁠Cardiology · AF · AnticoagulationIn 21,105 patients with AF at moderate-to-high stroke risk, edoxaban was non-inferior to warfarin for stroke or systemic embolism, with less bleeding.Read →
  • 2011ROCKET-AF⁠Cardiology · AF · AnticoagulationIn 14,264 patients with non-valvular AF at moderate-high stroke risk, rivaroxaban was non-inferior to warfarin for stroke or systemic embolism, with less intracranial bleeding.Read →
  • 2011ARISTOTLE Core⁠Cardiology · AF · AnticoagulationIn 18,201 patients with AF and ≥ 1 stroke risk factor, apixaban reduced stroke or systemic embolism, major bleeding and all-cause mortality compared with warfarin.Read →
  • 2009RE-LY Core⁠Cardiology · AF · AnticoagulationIn 18,113 patients with non-valvular AF, dabigatran 150 mg twice daily reduced stroke or systemic embolism compared with warfarin, with similar major bleeding.RR 0.66Read →
  • 1991SPAF⁠Cardiology · AF · antithromboticIn 1,330 patients with non-rheumatic atrial fibrillation, warfarin and aspirin each reduced ischaemic stroke or systemic embolism compared with placebo.Read →

Rate vs. early rhythm control6

  • 2021EARLY-AF⁠Cardiology · AF · AblationIn 303 patients with paroxysmal AF, first-line cryoballoon ablation reduced atrial arrhythmia recurrence compared with antiarrhythmic drugs.HR 0.48Read →
  • 2020EAST-AFNET 4⁠Cardiology · AF · Rate vs rhythmIn 2,789 patients with early AF (≤ 1 yr), early rhythm-control therapy reduced CV death, stroke or hospitalisation for HF or ACS versus usual care.HR 0.79Read →
  • 2019CABANA⁠Cardiology · AF · AblationIn 2,204 patients with symptomatic atrial fibrillation, catheter ablation did not significantly reduce death, disabling stroke, serious bleeding, or cardiac arrest compared with antiarrhythmic drug therapy.HR 0.8695% CI 0.65-1.15Read →
  • 2018CASTLE-AF⁠Cardiology · AF · AblationIn 363 patients with AF and heart failure with reduced ejection fraction, catheter ablation reduced death or heart-failure hospitalisation compared with medical therapy.HR 0.62Read →
  • 2010RACE II⁠Cardiology · AF · rate controlIn 614 patients with permanent atrial fibrillation, lenient rate control (resting heart rate <110 bpm) was non-inferior for a composite of cardiovascular events compared with strict rate control.12.9% vs 14.9%Read →
  • 2002AFFIRM⁠Cardiology · AF · Rate vs rhythmIn 4,060 patients with AF at high risk of stroke, a rhythm-control strategy did not reduce all-cause mortality compared with rate control.HR 1.1595% CI 0.99-1.34Read →

Catheter ablation1

  • 2016FIRE AND ICE⁠Cardiology · AF · AblationIn 762 patients with drug-refractory paroxysmal atrial fibrillation, cryoballoon ablation was non-inferior for clinical treatment failure compared with radiofrequency ablation.HR 0.9695% CI 0.76-1.22Read →

Left atrial appendage occlusion (upgraded to 2a)3

  • 2021LAAOS III⁠Cardiology · AF · surgical LAAOIn 4,660 patients with atrial fibrillation undergoing cardiac surgery, surgical left atrial appendage occlusion reduced ischaemic stroke or systemic embolism compared with no occlusion.HR 0.6795% CI 0.53-0.85Read →
  • 2020PRAGUE-17⁠Cardiology · AF · LAAOIn 402 high-risk patients with non-valvular atrial fibrillation, percutaneous left atrial appendage closure was non-inferior for a composite of cardiovascular and bleeding events compared with direct oral anticoagulants.HR 0.8495% CI 0.53-1.31Read →
  • 2014PROTECT AF⁠Cardiology · AF · LAAOIn 707 patients with non-valvular atrial fibrillation eligible for warfarin, Watchman left atrial appendage closure was non-inferior for stroke, systemic embolism, or cardiovascular death compared with warfarin.IRR 0.6095% CI 0.41-1.05Read →

Detection & monitoring1

  • 2014CRYSTAL AF⁠Cardiology · AF · cardiac monitorIn 441 patients with recent cryptogenic stroke, an insertable cardiac monitor detected atrial fibrillation more often than conventional follow-up.HR 6.495% CI 1.9-21.7Read →

Published since the guideline6

  • 2025OPTION⁠Cardiology · AF · LAAOIn 1,600 patients with atrial fibrillation who underwent catheter ablation, left atrial appendage closure was non-inferior for death, stroke, or systemic embolism and reduced bleeding compared with oral anticoagulation.5.3% vs 5.8%Read →
  • 2025OCEANIC-AF⁠Cardiology · AF · factor XIa inhibitorIn 14,810 patients with atrial fibrillation at high stroke risk, asundexian was inferior for prevention of stroke or systemic embolism compared with apixaban.HR 3.7995% CI 2.46-5.83Read →
  • 2024ARTESiA⁠Cardiology · AF · DOACIn 4,012 patients with device-detected subclinical AF and stroke risk factors, apixaban reduced stroke or systemic embolism compared with aspirin, at the cost of more bleeding.HR 0.6395% CI 0.45-0.88Read →
  • 2024FRAIL-AF⁠Cardiology · AF · DOAC switchIn 1,330 frail elderly patients with atrial fibrillation stable on a vitamin K antagonist, switching to a DOAC increased major or clinically relevant bleeding compared with continuing the vitamin K antagonist.HR 1.6995% CI 1.23-2.32Read →
  • 2023NOAH-AFNET 6⁠Cardiology · AF · DOACIn 2,536 patients with device-detected atrial high-rate episodes, edoxaban did not reduce cardiovascular death, stroke, or systemic embolism compared with placebo.HR 0.8195% CI 0.60-1.08Read →
  • 2023ADVENT⁠Cardiology · AF · AblationIn 607 patients with paroxysmal AF, pulsed-field ablation was non-inferior to conventional thermal ablation for treatment success and safety.73.3% vs 71.3%Read →

Cited landmark trials not yet in the register5

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2011AVERROES

    Apixaban vs. aspirin in AF patients unsuitable for a vitamin-K antagonist.

  • 2006ACTIVE-W

    Oral anticoagulation superior to aspirin + clopidogrel in AF.

  • 2015LEGACY

    Sustained weight loss reduced AF burden — the basis of the Class 1 risk-factor recommendation.

  • 2021AMULET IDE

    Head-to-head comparison of two left atrial appendage occluders.

  • 2020ELDERCARE-AF

    Low-dose edoxaban in very elderly patients ineligible for standard anticoagulation.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.